Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Breast cancer Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient, AND The condition must be hormone receptor positive. Treatment criteria: Must be treated by a medical practitioner; OR Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a medical practitioner, (ii) the prescription continues existing therapy with this medicine.
“MPA is a progestational agent.”
“PROVERA is an orally active progestational steroid having an apparent half-life of about 30 hours.”
“MPA is metabolised in vitro primarily by hydroxylation via the CYP3A4.”
Working under the parallel aged-care framework? Aged-care equivalent →
Endometrial cancer Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. Treatment criteria: Must be treated by a medical practitioner; OR Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a medical practitioner, (ii) the prescription continues existing therapy with this medicine.
Endometriosis Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.